Rapid Release Capsules Melatoni
PreclinicalSmall molecule
Rapid Release Capsules Melatoni is one of 17 small molecule programs targeting Oral Lichen Planus. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
16
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
17 competitors in Oral Lichen Planus
#DrugCompanyPhaseTrials
1Otezla
AmgenApproved
Kenalog
BBausch Health Americas, Inc.
Approved
Trexall
Jazz PharmaceuticalsApproved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Xeljanz
PPrism Pharmaceuticals
Approved
Celestone
SSchering-Plough
Approved
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Rapamune
PPrism Pharmaceuticals
Approved
Rayos
RRoxane Laboratories
Approved
Flagyl
DDePuy Orthopaedics
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- HHams Hamed Abdelrahman